title: [Progress in 2008 for acid related diseases].
abstract: The treatment of reflux disease did not change in the review period. PPI therapy remains the first line treatment and surgery the second line approach. Endoscopic anti-reflux procedures should be only performed in controlled studies. Beside the classic triple therapy, sequential treatment of Helicobacter pylori infection can today be considered as a first line therapy. PPI are effective in the prevention of gastroduodenal lesions and in the treatment of dyspeptic symptoms induced by NSAIDs treatment. Only patients younger then 65 years and without any risk factors do not need a preventive PPI prescription during classic NSAIDS treatment.
authors.affiliation: Service de gastroentérologie et d'hépatologie, CHUV, 1011 Lausanne.
authors.forename: P
authors.initials: P
authors.lastname: Jornod
authors.forename: D
authors.initials: D
authors.lastname: Vouillamoz
authors.forename: F
authors.initials: F
authors.lastname: Viani
authors.forename: C
authors.initials: C
authors.lastname: Nichita
authors.forename: G
authors.initials: G
authors.lastname: Dorta
mesh_terms: D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D013505:Digestive System Surgical Procedures; D005764:Gastroesophageal Reflux / Q000628:therapy*; D016481:Helicobacter Infections / Q000188:drug therapy; D006801:Humans; D054328:Proton Pump Inhibitors / Q000627:therapeutic use
chemical_list: D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors